Demographics and clinical characteristics of the included patients
| Sex | Age (years) | Inflammatory disease | Biological DMARD | Conventional DMARD | Steroids |
| F | 44 | Psoriatic arthritis | Golimumab | Leflunomide | 5 mg prednisolone |
| F | 35 | Psoriatic arthritis | Certolizumab pegol | – | – |
| F | 43 | Rheumatoid arthritis | Certolizumab pegol | – | 5 mg prednisolone |
| M | 46 | MCTD | – | Hydroxychloroquine | – |
| F | 39 | Rheumatoid arthritis | Etanercept | Leflunomide | – |
| F | 51 | Rheumatoid arthritis | – | Sulfasalazine | – |
| F | 65 | Spondyloarthropathy | Infliximab | – | – |
| M | 38 | Spondyloarthropathy | Etanercept | – | – |
| F | 45 | Sarcoidosis | Infliximab | – | 15 mg prednisolone |
| F | 33 | Rheumatoid arthritis | Certolizumab pegol | – | – |
| M | 84 | Giant cell vasculitis | Tocilizumab | – | 5 mg prednisolone |
| F | 47 | Psoriasis | Ixekizumab | – | – |
| M | 83 | Rheumatoid arthritis | Etanercept | – | 2.5 mg prednisolone |
| M | 38 | Crohn’s disease | Vedolizumab | – | – |
| F | 53 | Rheumatoid arthritis | – | Leflunomide | 7 mg prednisolone |
| F | 24 | Systemic lupus erythematosus | – | Hydroxychloroquine | – |
| M | 42 | Psoriasis | Adalimumab | – | – |
| F | 54 | Rheumatoid arthritis | Adalimumab | – | – |
| M | 58 | Spondyloarthropathy | Secukinumab | – | – |
| F | 51 | Psoriasis | Secukinumab | – | – |
| F | 53 | Crohn’s disease | Infliximab | – | – |
| M | 61 | Psoriasis | Ustekinumab | – | – |
| M | 36 | Systemic lupus erythematosus | Belimumab | Hydroxychloroquine | – |
| F | 89 | Myositis | – | – | 2.5 mg prednisolone |
| F | 49 | Multiple sclerosis/Crohn’s disease | – | Azathioprine | – |
| F | 54 | Rheumatoid arthritis | Adalimumab | – | – |
DMARDs, disease-modifying antirheumatic drugs; MCTD, mixed connective tissue diseases.